Virginia is currently home to 1880 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Register for Updates
Can Video Assisted Therapy Replace In-Person Occupational Therapy After Hand Surgery: A Noninferiority Study
NCT04625244
Recruiting
This study will investigate a video assisted, home therapy program where participants complete hand therapy on their own following thumb arthroplasty. In this program, participants will receive prerecorded informational videos. Half of the participants in this study will do standard of care, in-person therapy. The other half will be enrolled in the home therapy program. Participants will fill out an assessment of their physical ability before surgery and again three months after surgery. These a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: Carilion Clinic Orthopaedic Surgery, Roanoke, Virginia
Conditions: Thumb Osteoarthritis
Register for Updates
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
NCT03748186
Recruiting
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
Validation of a Salivary miRNA Diagnostic Test for ASD
NCT05418023
Recruiting
This study involves sample collection to identify biomarkers relating to Autism Spectrum Disorder(ASD) in the saliva of children who are between the ages of 18 months to 6 years and 11 months. Participants will at each timepoint have a non-invasive saliva swab collected and complete a brief demographic and medical history questionnaire as well. Children in the pediatric/provider setting who will receive a referral for an ASD diagnosis because they were determined to have a suspicion of developin... Read More
Gender:
All
Ages:
Between 18 months and 7 years
Trial Updated:
02/06/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Autism Spectrum Disorder, Developmental Delay
Register for Updates
Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03596905
Recruiting
This study of the efficacy and safety of Plecanatide in children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C)
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/06/2023
Locations: Synergy Research Site, Newport News, Virginia
Conditions: Irritable Bowel Syndrome With Constipation
Register for Updates
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05508568
Recruiting
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of r... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
01/30/2023
Locations: Virginia Urology Center, Richmond, Virginia
Conditions: Bladder Cancer
Register for Updates
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127
Recruiting
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2023
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Register for Updates
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
NCT04295811
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Richmond, Virginia
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Register for Updates
Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
NCT04502316
Recruiting
The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.
Gender:
All
Ages:
All
Trial Updated:
01/21/2023
Locations: Carient Heart & Vascular, Manassas, Virginia
Conditions: Heart Failure
Register for Updates
Vaginal Cuff Brachytherapy Fractionation Study
NCT03785288
Recruiting
The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Endometrial Cancer
Register for Updates
Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers
NCT05601856
Recruiting
Spousal caregivers of Alzheimer's Dementia (AD) patients have an elevated risk of developing AD in the future. Past studies have shown the presence of serum indicators correlated with gut biome dysfunction in AD patients. We hypothesize that the same gut biome dysfunction may be present in spousal caregivers of AD patients.
Gender:
All
Ages:
Between 65 years and 90 years
Trial Updated:
01/18/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Alzheimer Disease, Gut Biome
Register for Updates
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT03272334
Recruiting
This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine a safe dose of the combination of PBZ and HER2 BATs in 3 to 18 patients. In the phase II portion, an additional 12 patients will be treated at the selected dose to further evaluate the safety and preliminary efficacy. Study treatment includes a combination of 8 infusions of BATs using a previously estab... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: Ashley Donihee, Charlottesville, Virginia
Conditions: Metastatic Breast Cancer
Register for Updates